Vedolizumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Target | Integrin α4β7 |
| Clinical data | |
| Trade names | Entyvio |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a614034 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | Intravenous |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6528H10072N1732O2042S42 |
| Molar mass | 146836.99 g·mol−1 |
| (what is this?) (verify) | |
Vedolizumab, sold under the brand name Entyvio, is a monoclonal antibody medication developed by Takeda Oncology for the treatment of ulcerative colitis and Crohn's disease.[5] It binds to integrin α4β7 (LPAM-1, lymphocyte Peyer's patch adhesion molecule 1, a dimer of Integrin alpha-4 and Integrin beta-7),[5][6] blocking the α4β7 integrin results in gut-selective anti-inflammatory activity.[7]
- ^ "Prescription medicines: registration of new chemical entities in Australia, 2014". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.
- ^ "Health Canada New Drug Authorizations: 2015 Highlights". Health Canada. 4 May 2016. Retrieved 7 April 2024.
- ^ "Entyvio- vedolizumab injection, powder, lyophilized, for solution". DailyMed. 3 April 2020. Retrieved 12 October 2020.
- ^ "Entyvio EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 12 October 2020.
- ^ a b "Statement on a Nonproprietary Name Adopted by the USAN Council - Vedolizumab" (PDF). United States Adopted Names Council. American Medical Association. ama-assn.org. Archived from the original (PDF) on 20 February 2012.
- ^ Soler D, Chapman T, Yang LL, Wyant T, Egan R, Fedyk ER (September 2009). "The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases". The Journal of Pharmacology and Experimental Therapeutics. 330 (3): 864–875. doi:10.1124/jpet.109.153973. PMID 19509315. S2CID 257985.
- ^ Fedyk ER, Wyant T, Yang LL, Csizmadia V, Burke K, Yang H, et al. (November 2012). "Exclusive antagonism of the α4 β7 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates". Inflammatory Bowel Diseases. 18 (11): 2107–2119. doi:10.1002/ibd.22940. PMID 22419649. S2CID 12242501.